VEPESID: ETOPOSIDE CAPSULES.
The ETOPOSIDE CAPSULES is a the manufacturer industrial component. Key specifications include features_provided: INDIVIDUALLY SEALED, primary_container_type: STRIP, protective_storage_feature: ANTINEOPLASTIC DRUG AND REQUIRES REFRIGERATION STORAGE BETWEEN 2 TO 8 DEG CELSIUS AND SUBJECT TO DAMAGE BY FREEZING, active_medicament_medicinal_strength: 50.000 MILLIGRAMS ETOPOSIDE ACTIVE INGREDIENT, part_name_assigned_by_controlling_agency: ETOPOSIDE CAPSULES 50MG I.S. 20S PG, capsule_primary_container_content_quantity: 20.000.
This part is cataloged in the U.S. Government catalog under NSN 6505-01-278-1124, indicating validated use in U.S. government and defense logistics supply chains.
Available through authorized enterprise resellers and TPM (Third Party Maintenance) channels. Verify compatibility with your specific system configuration before ordering.
| features_provided | INDIVIDUALLY SEALED |
| primary_container_type | STRIP |
| protective_storage_feature | ANTINEOPLASTIC DRUG AND REQUIRES REFRIGERATION STORAGE BETWEEN 2 TO 8 DEG CELSIUS AND SUBJECT TO DAMAGE BY FREEZING |
| active_medicament_medicinal_strength | 50.000 MILLIGRAMS ETOPOSIDE ACTIVE INGREDIENT |
| part_name_assigned_by_controlling_agency | ETOPOSIDE CAPSULES 50MG I.S. 20S PG |
| capsule_primary_container_content_quantity | 20.000 |
| NSN | 6505-01-278-1124 |
| FEATURES PROVIDED | INDIVIDUALLY SEALED |
| PRIMARY CONTAINER TYPE | STRIP |
| PROTECTIVE STORAGE FEATURE | ANTINEOPLASTIC DRUG AND REQUIRES REFRIGERATION STORAGE BETWEEN 2 TO 8 DEG CELSIUS AND SUBJECT TO DAMAGE BY FREEZING |
| CAPSULE PRIMARY CONTAINER CONTENT QUANTITY | 20.000 |
| PART NAME ASSIGNED BY CONTROLLING AGENCY | ETOPOSIDE CAPSULES 50MG I.S. 20S PG |
| ACTIVE MEDICAMENT MEDICINAL STRENGTH | 50.000 MILLIGRAMS ETOPOSIDE ACTIVE INGREDIENT |